# Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects

> **NCT01516307** · PHASE2 · COMPLETED · sponsor: **OBI Pharma, Inc** · enrollment: 349 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **BIOLOGICAL:** OPT-822/OPT-821(30 μg/100 μg)
- **BIOLOGICAL:** Phosphate Buffer Saline (PBS)
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT01516307
- **Lead sponsor:** OBI Pharma, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2016-08
- **Final completion:** 2019-08
- **Target enrollment:** 349 (ACTUAL)
- **Last updated:** 2020-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01516307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01516307, "Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01516307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*